Weekly Investment Analysts’ Ratings Changes for Bruker (BRKR)

Bruker (NASDAQ: BRKR) recently received a number of ratings updates from brokerages and research firms:

• 12/19/2024 – Bruker is now covered by analysts at Guggenheim. They set a “buy” rating and a $72.00 price target on the stock.
• 12/13/2024 – Bruker had its price target raised by analysts at Bank of America Co. from $78.00 to $80.00. They now have a “buy” rating on the stock.
• 12/10/2024 – Bruker is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $66.00 price target on the stock.
• 12/5/2024 – Bruker was upgraded by analysts at The Goldman Sachs Group, Inc. from a “sell” rating to a “neutral” rating. They now have a $60.00 price target on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at Wells Fargo & Company from $78.00 to $75.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at Barclays PLC from $75.00 to $69.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at TD Cowen from $72.00 to $70.00. They now have a “hold” rating on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a “buy” rating on the stock.

Bruker Trading Down 0.2 %

NASDAQ:BRKR traded down $0.09 on Thursday, reaching $55.29. 2,548,354 shares of the company’s stock were exchanged, compared to its average volume of 1,124,468. Bruker Co. has a 52-week low of $48.07 and a 52-week high of $94.86. The business has a fifty day moving average of $58.16 and a 200-day moving average of $62.49. The firm has a market capitalization of $8.38 billion, a price-to-earnings ratio of 26.58, a price-to-earnings-growth ratio of 4.00 and a beta of 1.18. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same period last year, the firm posted $0.74 earnings per share. Bruker’s revenue for the quarter was up 16.4% on a year-over-year basis. As a group, analysts expect that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.36%. The ex-dividend date was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien bought 100,000 shares of the stock in a transaction on Monday, November 18th. The shares were bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently modified their holdings of the company. First Horizon Advisors Inc. grew its holdings in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares during the period. True Wealth Design LLC grew its stake in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after buying an additional 510 shares during the period. UMB Bank n.a. increased its position in shares of Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Bruker in the 2nd quarter valued at $52,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.